Search
Pancuronium
go.drugbank.com/drugs/DB01337ApprovedAs a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release.
Acetrizoic acid
go.drugbank.com/drugs/DB09347ApprovedWithdrawn[A32135] It was first synthesized by Wallingford in 1953[A32136] and it was filled in the FDA by the Johnson & Johnson subsidiary, Cilag Chemie AG, on February 8th, 1978.
Ephedrine
go.drugbank.com/drugs/DB01364ApprovedInvestigational[L12972] Ephedrine and [phenylephrine] are still used to treat hypotension, but their use in other indications has decreased due to the development of more selective adrenergic agonists.
Volanesorsen
go.drugbank.com/drugs/DB15067Approved[L16621] Volanesorsen was granted a conditional approval by the European Medicines Agency.[L16621]
Saquinavir
go.drugbank.com/drugs/DB01232ApprovedInvestigationalIn 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared … [A214382] While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%),[L3450] its current indications require the co-administration of ritonavir - a potent enzyme
Aminopterin
go.drugbank.com/drugs/DB08878ApprovedWithdrawnIn the 1950's its production was discontinued in favor of methotrexate, which is less potent but less toxic. Off label, aminopterin has also been used in the treatment of psoriasis.
Eslicarbazepine acetate
go.drugbank.com/drugs/DB09119ApprovedInvestigationalEslicarbazepine's mechanism of action is not well understood, but it is known that it does exert anticonvulsant activity by inhibiting repeated neuronal firing and stabilizing the inactivated state of
Emapalumab
go.drugbank.com/drugs/DB14724ApprovedInvestigationalEmapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018. … [L4840] As well, emapalumab was given the status of PRIME by the EMA.[L4845]
Anidulafungin
go.drugbank.com/drugs/DB00362ApprovedAnidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366.
Niclosamide
go.drugbank.com/drugs/DB06803ApprovedInvestigationalVet approvedNiclosamide, once marketed in the US under the brand name Niclocide, was voluntarily withdrawn from market by Bayer in 1996.[L11860]